Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

doi:10.1016/S0304-3940(01)02384-9

Neuroscience Letters

Volume 316, Issue 2, 18 December 2001, Pages 67-70

https://doi.org/10.1016/S0304-3940(01)02384-9 Get rights and content

Abstract

Adult C57BL/6 mice were injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Intrastriatal transplantation of bone marrow stromal cells (MSCs) was performed 1 week after MPTP administration. MSCs were harvested from donor adult mice, and then cultured and prelabeled with bromodeoxyuridine (BrdU). MPTP-Parkinson's disease (PD) mice treated with intrastriatal injection of phosphate-buffered saline (PBS), and normal non-MPTP mice were used as controls. MPTP-PD mice with MSC intrastriatal transplantation exhibit significant improvement on the rotarod test (P<0.05) at day 35 compared with PBS controls. Immunohistochemistry shows that BrdU reactive cells survive in the transplanted areas in the MPTP-PD striatum at least 4 weeks after administration. Scattered BrdU reactive cells express tyrosine hydroxylase (TH) immunoreactivity. Our findings suggest that MSCs injected intrastriatally survive, express dopaminergic protein TH immunoreactivity, and promote functional recovery.

Section snippets

Acknowledgements

The authors wish to thank Cecylia Powers and Cynthia Roberts for technical assistance. This work was supported by NINDS grants PO1 NS23393.

References (18)

K. Bankiewicz et al.
Trophism, transplantation, and animal models of Parkinson's disease
Exp. Neurol.
(1993)
C.J. Eaves et al.
Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer
Blood
(1991)
G. Rozas et al.
Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test
Brain Res.
(1997)
M. Abercrombie
Estimation of nuclear population from microtome sections
Anat. Rec.
(1946)
S.A. Azizi et al.
Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats – similarities to astrocyte grafts
Proc. Natl. Acad. Sci. USA
(1998)
R.S. Burns et al.
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Proc. Natl. Acad. Sci. USA
(1983)
M. Chopp et al.
Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation (in process citation)
Neuroreport
(2000)
M.A. Eglitis et al.
Targeting of marrow-derived astrocytes to the ischemic brain
Neuroreport
(1999)
G. Ferrari et al.
Muscle regeneration by bone marrow-derived myogenic progenitors
Science
(1998)

There are more references available in the full text version of this article.

Cited by (257)

Third-party bone marrow–derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial
2021, American Journal of Transplantation
Mesenchymal stromal cells (MSC) have emerged as a promising therapy to minimize the immunosuppressive regimen or induce tolerance in solid organ transplantation. In this randomized open-label phase Ib/IIa clinical trial, 20 liver transplant patients were randomly allocated (1:1) to receive a single pretransplant intravenous infusion of third-party bone marrow–derived MSC or standard of care alone. The primary endpoint was the safety profile of MSC administration during the 1-year follow-up. In all, 19 patients completed the study, and none of those who received MSC experienced infusion-related complications. The incidence of serious and non-serious adverse events was similar in the two groups. Circulating Treg/memory Treg and tolerant NK subset of CD56^bright NK cells increased slightly over baseline, albeit not to a statistically significant extent, in MSC-treated patients but not in the control group. Graft function and survival, as well as histologic parameters and intragraft expression of tolerance-associated transcripts in 1-year protocol biopsies were similar in the two groups. In conclusion, pretransplant MSC infusion in liver transplant recipients was safe and induced mild positive changes in immunoregulatory T and NK cells in the peripheral blood. This study opens the way for a trial on possible tolerogenic efficacy of MSC in liver transplantation. ClinicalTrials.gov identifier: NCT02260375.
Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier
2020, European Journal of Cell Biology
Neurodegenerative disorders are a variety of diseases including Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) along with some other less common diseases generally described by the advanced deterioration of central or peripheral nervous system, structurally or functionally. In the last two decades, mesenchymal stromal cells (MSCs) due to their unique assets encompassing self-renewal, multipotency and accessibility in association with low ethical concern open new frontiers in the context of neurodegenerative diseases therapy. Interestingly, MSCs can be differentiated into endodermal and ectodermal lineages (e.g., neurons, oligodendrocyte, and astrocyte), and thus could be employed to advance cell-based therapeutic strategy. Additionally, as inflammation ordinarily ensues as a local response provoked by microglia in the neurodegenerative diseases, MSCs therapy because of their pronounced immunomodulatory properties is noticed as a rational approach for their treatment. Recently, varied types of studies have been mostly carried out in vitro and rodent models using MSCs upon their procurement from various sources and expansion. The promising results of the studies in rodent models have motivated researchers to design and perform several clinical trials, with a speedily rising number. In the current review, we aim to deliver a brief overview of MSCs sources, expansion strategies, and their immunosuppressive characteristics and discuss credible functional mechanisms exerted by MSCs to treat neurodegenerative disorders, covering AD, PD, ALS, MS, and HD.
The therapeutic potential of exogenous adult stem cells for the injured central nervous system
2020, Handbook of Innovations in Central Nervous System Regenerative Medicine
The multimodal therapeutic properties of stem-cell therapies hold considerable promise for addressing the complex pathologies arising from damage to the central nervous system (CNS). Stem cells derived from embryonic or fetal sources are burdened with safety, practical, and ethical concerns, so there is considerable interest in stem cells that can be obtained from adult tissues. Transplantation of adult stem cells, be they of somatic origin (e.g., neural stem cells or mesenchymal stromal cells) or acquired through reprogramming of somatic cells (e.g., induced pluripotent stem cells), has been shown to yield myriad benefits at the molecular, anatomical, and functional levels in preclinical animal models of various CNS disorders. However, clinical translation has thus far been impeded by only modest efficacy outcomes in clinical trials, speaking to a need for greater consistency and controls in such studies. We provide a brief overview of adult stem cells and summarize the findings of their preclinical and clinical therapeutic applications in the injured CNS.
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
2019, Mayo Clinic Proceedings
Mesenchymal stromal cells are multipotent cells that are being used to treat a variety of medical conditions. Over the past decade, there has been considerable excitement about using MSCs to treat neurodegenerative diseases, which are diseases that are typically fatal and without other robust therapies. In this review, we discuss the proposed MSC mechanisms of action in neurodegenerative diseases, which include growth factor secretion, exosome secretion, and attenuation of neuroinflammation. We then provide a summary of preclinical and early clinical work on MSC therapies in amyotrophic lateral sclerosis, multiple system atrophy, Parkinson disease, and Alzheimer disease. Continued rigorous and controlled studies of MSC therapies will be critical in order to establish efficacy and protect patients from possible untoward effects.
Cell therapy for parkinson’s disease
2019, Comprehensive Biotechnology
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. Current therapeutic approaches for PD provide temporary symptomatic relief, but none change the course of the disease. Pharmacological therapies are valuable but are not long lasting, and surgical treatment is actually no better than current medications. Transplantation of embryonic mesencephalic cells, based on an open-label pilot study, has encouraged cell therapy as an alternative treatment for PD. However, two recent double-blind placebo-controlled transplantation trials did not confirm the therapeutic effect observed in the open-label study and thus raised concerns about the feasibility of treatment using transplantation of fetal brain-derived mesencephalic cells. Similar results also occurred when retinal pigment epithelial (RPE) cells were used to treat PD patients.
Recent advances in producing dopaminergic (DA) neurons from human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) have inspired our hope for an alternative cell source for treating PD. Yet, there are noticeable challenges and concerns, including production of genetically stable DA neurons, overcoming host immune rejection, prevention of tumor formation in the graft, and integration of grafted DA neurons into host circuits. This article provides an overview of selective cell sources and cell differentiation stages in treating PD patients.
Effects of mesenchymal stem cell on dopaminergic neurons, motor and memory functions in animal models of Parkinson’s disease: a systematic review and meta-analysis
2024, Neural Regeneration Research

View all citing articles on Scopus

View full text

Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

Abstract

Section snippets

Acknowledgements

Exp. Neurol.

Blood

Brain Res.

Estimation of nuclear population from microtome sections

Anat. Rec.

Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats – similarities to astrocyte grafts

Proc. Natl. Acad. Sci. USA

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Proc. Natl. Acad. Sci. USA

Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation (in process citation)

Neuroreport

Targeting of marrow-derived astrocytes to the ischemic brain

Neuroreport

Muscle regeneration by bone marrow-derived myogenic progenitors

Science